Palma Fedele, Director of the Oncology Unit at Dario Camberlingo Hospital shared on LinkedIn:
“Published today in Breast Cancer Research and Treatment: our multicenter real-world study on early first-line treatment attrition in metastatic TNBC after neoadjuvant chemo-immunotherapy.
Nearly one-third of patients did not start systemic therapy within 90 days, highlighting the need for earlier surveillance and multidisciplinary care.”
Title: Early First-Line Therapeutic Attrition After Metastatic Recurrence in Triple-Negative Breast Cancer Following Neoadjuvant ChemoImmunotherapy: A Multicenter Real-World Study
Authors: Palma Fedele, Alessandro Rizzo, Matteo Landriscina, Stefania Luigia Stucci, Carmela Inneo, Maria Morritti, Franco Morelli, Francesco Giuliani, Lucia Moraca, Teresa Masselli Mascia, Giuseppe Cairo, Marianna Giampaglia, Beatrice Tedesco, Assunta Melaccio, Felicia M. Maselli, Antonio Gnoni, Antonella Licchetta, Federica Fumai, Elsa Vitale, Fiorella Restaino Marino, Emanuela Zifarone, Laura Lanotte, Gennaro Gadaleta-Caldarola, Raffaele Ardito
Read the full article.
You can also read:
